Angioline

Angiolain (Angiolain Interventional Device, LLC) is a Russian developer and manufacturer of medical devices, tools and consumables for interventional cardiology (X-ray endovascular diagnosis and treatment), cardiovascular and general surgery.

History

2024: Co-owner of Angiolain, a manufacturer of medical devices for cardiology, was detained in Moscow

In June 2022, it became known about the appointment of Natalia Lebedeva as the new general director of Angiolain. The change of chapter came amid a corporate conflict within the manufacturer of medical devices for interventional cardiac surgery. Read more here.

2022

Russian Medical Production of Core Stents Killed by Raiders Attack

In June 2022, it became known that Angiolaine had stopped the production of medical devices for cardiac surgery. The company explained the termination of production "certain disagreements between shareholders."

According to the VChK-OGPU Telegram channel, the medical production of stents for cores has been "ruined due to the attack of raiders." The report says that on June 1, 2022, at a meeting of shareholders, the company's investment consultant Natalya Lebedeva elected herself the general director, removing Andrei Kudryashov from the post of current head. The remaining shareholders intend to appeal this decision.

Russian medical production of stents for cores threatened due to attack by raiders

The agency "Center for Business Life," referring to the current general director of Angiolain JSC Andrei Kudryashov, reported that mass layoffs began in the company, the production of medical goods was stopped due to the departure of key employees. On June 9, 2022, the plant's equipment was seized.

Earlier, the founders of Angiolain, Andrei Kudryashov and Alexei Frantsev, were expelled from the shareholders by decision of the Arbitration Court of the Novosibirsk Region. In total, entrepreneurs owned almost three quarters of the company's shares (37.2% each).

During the proceedings, the court considered that Kudryashov and the French caused significant harm to the company during the corporate conflict in 2017-2022. As RBC wrote, Lebedeva stated that she was removed from decision-making, and the actions of other shareholders had the goal of reducing her share in JSC (25%). She received shares in return for investments in 2013.

According to VChK-OGPU, under the leadership of Andrei Kudryashov and Alexei Frantsuzov, Angiolain won 30% of the Russian stent market from American monopolists. The dubious decision of the judges, destroying Angiolaine, could return billions of dollars to suppliers from the United States - it is difficult not to suspect corruption, the Telegram channel notes.^[1]

Appointment of Natalia Lebedeva to the position of general director of Angiolaine

In June 2022, it became known about the appointment of Natalia Lebedeva as the new general director of Angiolain. The change of chapter came amid a corporate conflict within the manufacturer of medical devices for interventional cardiac surgery. Read more here.

2019

Opening of a production site in the science city "Koltsovo"

On September 18, 2019 TAdviser , it became known that Novosibirsk the opening of the Angiolain production site took place. The ceremony was attended by First Deputy Chairman State Duma RUSSIAN FEDERATION Alexander Zhukov, Novosibirsk region Andrey Travnikov Governor, Member, of the Federation Council of the Federal Assembly of the Russian Federation Vladimir Gorodetsky Director of the Department of Regional, Industrial Policy and Project Management Ministry of Industry and Trade of the Russian Federation Vitaly Khocenko, Director of Angiolain Andrey Kudryashov and other officials.

The production site was opened on the territory of the Biotechnopark innovation center in the Koltsovo science city. The open research and production center occupies 9.5 thousand square meters, which will increase the production facilities previously available at Angiolain by more than half. The complex is of great importance both for the region and for the country as a whole: it is planned to develop and serial production of innovative devices and equipment for cardiovascular medicine. The most important of these will be vascular retrievers for the extraction of blood clots, percutaneously implantable aortic valves and aortic stent graphs. Thanks to the opening of the site, more than 150 jobs were created. The company's investment in construction amounted to more than 500 million rubles.

As a result of the commissioning of a new production site, we will be able to increase the production of innovative products for heart surgery, which will contribute to the development of medicine in our country. The administration of the Novosibirsk region helps us to be not only a reliable partner of leading clinics that implement the state import substitution program in medicine, but also successfully implement the mission of our company, which sounds like "More saved lives,

The new production site is not just an important step in the development of the company, it is another high-tech production in the region. That is why the investment project "Angiolain" received support - as a flagship - as part of the program of reindustrialization of the economy of the Novosibirsk region,

Obtaining Russian Exporter and Made in Russia quality marks

On March 7, 2019, Angiolain, a manufacturer of medical devices for interventional cardiology, announced the receipt of Russian Exporter and Made in Russia quality marks following voluntary certification by the Russian Export Center. Based on the issued certificates of conformity, Angiolaine now has the right to place the Russian Exporter sign, which guarantees that the company is a reliable manufacturer and a bona fide supplier, on its website and in advertising products, and the Made in Russia sign, confirming compliance with world standards, on the packaging of medical products and the medical products themselves.

Compliance certificates were obtained by the company based on the results of a comprehensive assessment of the image and business reputation for a number of parameters, including development history, product quality, personnel competence and production safety. The receipt of special quality marks by Angiolain JSC creates the prerequisites for further increasing the brand awareness of the company in foreign markets and is one of the factors contributing to the effective sale of products abroad.

Angiolain is successfully expanding into the CIS, Vietnam and the Middle East. The company plans to receive a CE brand, a special mark that certifies the compliance of products with European Union standards, and access to European markets.

The launch of the production of medical devices in Koltsovo is scheduled for August

On February 1, 2019, it became known about the plans of the Russian manufacturer of medical devices Angiolain to launch a production site on the territory of Biotechnopark Koltsovo (Novosibirsk Region), where the company expects to establish the production of aortic valves, stent retrievers for the extraction of blood clots, aortic stent grafts. The volume of investments in the project amounted to about 500 million rubles. It is expected that the launch of the facility will allow Angiolaine to expand its product portfolio by 3-5 times and increase production capacity by 4 times.

According to the estimates of the director of Angiolain Andrei Kudryashov, construction work at the facility will be completed by mid-March 2019, after which the stage of obtaining a license for medical production and installation of equipment will begin. The company hopes to prepare all the documents in July, and to launch production in August 2019. According to Kudryashov, with the launch of the site, the company will have the opportunity to at least double the production of coronary stents in order to meet the needs of the Russian Federation.

As of February 2019, the total area of ​ ​ the object being created in Koltsovo will be 4.5 thousand square meters, of which half will be occupied by production, and about 1 thousand square meters - the R&D center. The number of employed personnel will be from 150 to 300^[2]

In 2018 Russia , 284 thousand stents were purchased, we shipped 62 thousand, although we can already produce Campus about 120 thousand a year on the site, "says Kudryashov. - The stent market is quite complex, since many medical centers, for various reasons, prefer to buy imported products, even at inflated prices - up to 30%. At the same time, we see that foreign manufacturers, seeing that our products meet world standards, but at the same time cheaper, began to revise their prices.

According to the director of Angiolain, as of January 2019, taking into account the company LLC Stentex (joint venture the American of the company Medtronic and the Russian group of companies - Renova approx.), From TAdviser 25 to 40% of the Russian market is provided by stents of domestic production. However, according to Kudryashov, this is a conditional indicator, since Stentex produces its products in. Ireland

Speaking about the company's plans to enter foreign markets, Andrei Kudryashov admitted that it would be extremely difficult to do this due to high competition.

We already have sales abroad, but these are more image deals than serious business. Many countries have their own manufacturers of medical products, and they control local markets where there is very high competition, "he said. - In order to enter any foreign market, you need to have such an advantage as the ability to dump. And for this, the company must have good positions in its country and earn money to subsidize foreign sales.

However, Kudryashov does not exclude that the products that the company plans to produce at the Koltsovo site may be in demand abroad. So, in 2019, Angiolain intends to start producing an aortic valve, a stent retriever for extracting blood clots, and an aortic stent graft. As of February 1, these products are registered and after installation of the lines will be immediately put into production.^[3]

Manufacturing and Sales Office

As of January 2019, Angiolaine production is located in Novosibirsk. At the same time, the company has a sales office in Moscow.

The range of products of the company has more than 20 items and is constantly expanding. The company's products are used in more than 210 clinics in 63 regions of Russia.

2018: QMS certification to ISO 13485:2016 and EN ISO 13485:2016

In 2018, a certificate was obtained confirming the compliance of the Angiolain quality management system with the requirements of the international standard ISO 13485:2016 and EN ISO 13485:2016. At the same time, the scope of the certificate is expanded - endocardial devices, surgical suture material with needles are added.

2017: Investment of about 500 million rubles in the launch of production in Koltsovo

In 2017, Angiolain began construction of a site on the territory of Biotechnopark in Koltsovo with a total investment of about 500 million rubles. In particular, the cost of the production complex is estimated at 250-300 million rubles. The company plans to spend the same amount on equipment in the first stage of the project. Then the next stage of investment and retrofitting of production is assumed.

The company intends to enter the facility in June 2017. The total area of ​ ​ the production complex will be 8.5 thousand square meters, including the industrial zone - 3.5-4 thousand square meters, the research unit - 1.2 thousand square meters.

The company intends to complete the project in 2020, the payback period, according to preliminary estimates, will be 5 years. The project will be financed at the expense of Angiolain's own funds. After the launch of the facility by 2021, the revenue for the group of companies, according to the company's experts, will amount to 6.1 billion rubles, for the project - about 4 billion rubles, and net profit - 1.4 billion.

We understand that construction will take more than one day, so from 2018 we plan to expand production on leased areas in order to transfer equipment and technologies to it by the launch of our own complex, "said Andrei Kudryashov, director of Angiolain.

At the Koltsovo site, the company is preparing to launch four products on the market, for which there is a high level of dissatisfaction in Russian healthcare.^[4]

For example, coronary stents in our country are produced three times less than in the leading countries of the world, and for other medical devices the situation is even worse. For example, operations with an aortic valve, which is given to age patients, in our country we carry out only up to 600 per year, with a need of up to 40 thousand. In Russia, these valves (as of May 2017 - approx. TAdviser) are not produced, and the cost of foreign analogues is 1.5 million rubles, which is unbearable for the budget. For this medical product, we conduct preclinical tests on animals, - said Andrei Kudryashov. - For venous implants of the cava filter, the volume of implants is 5 thousand per year, and more than 100 thousand people die without surgery. Implants of the occluder of the ear of the left atrium are installed in hardly thousands of patients, and 75 thousand people a year die from a stroke due to the fact that blood clots enter the head from the heart. Documents on these medical products are submitted for registration to Roszdravnadzor. Stent-graft vascular implants on the market are 5-10 times smaller than necessary.

2013: QMS certification according to ISO 9001 and ISO 13485

In 2013, Angiolain received certificates for compliance of the quality management system with the requirements of ISO 9001 and ISO 13485 standards.

2012: Start of production of stents "Calypso"

In 2012, the production of Calypso coronary stents with a bioresorbable coating releasing sirolimus began.

2011

Since 2011, Angiolain has produced 15 types of products for interventional cardiology.

2009: Start of production of Sine stents and Hummingbirds catheters

In 2009, the production of Sinus metal coronary stents and Hummingbird balloon catheters began.

2007: Foundation

In 2007, the Angiolain Intervention Device company was founded.

Notes